NCT06718439 Hemoglobin Levels for Blood Transfusions During and After Surgery
| NCT ID | NCT06718439 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ottawa Hospital Research Institute |
| Condition | Blood Transfusion |
| Study Type | INTERVENTIONAL |
| Enrollment | 384 participants |
| Start Date | 2025-04-16 |
| Primary Completion | 2026-04-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 384 participants in total. It began in 2025-04-16 with a primary completion date of 2026-04-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this pilot clinical trial is to learn if it is achievable to conduct a large-scale clinical trial whereby, the investigators will compare two ways of deciding when to give a blood transfusion during surgery. Participants in this study are adults undergoing surgery with a risk of significant blood loss. The main question it aims to answer is: * Is a trial designed to definitively test and compare two different red blood cell transfusion strategies feasible? Participants will: * Receive blood transfusions during surgery based on a higher (less than 90 g/L) or a lower (less than 70 g/L) hemoglobin value. * Complete questionnaires at 30 and 90 days after surgery.
Eligibility Criteria
Inclusion Criteria: * Adult patients, age ≥18. * Elective or urgent surgery. * Risk of red blood cell transfusion of at least 10 percent. * Preoperative hemoglobin of less than 130 g/L. * Intraoperative hemoglobin of ≤ 100 g/L at any time during surgery. Exclusion Criteria: * Active major hemorrhage as indication for surgery (e.g. ruptured aneurysm, polytrauma, etc.). * Acute coronary syndrome or myocardial infarction within the past 6 weeks. * Cardiac surgery. * Liver transplantation. * Surgery for moderate to severe (Glasgow Coma Scale (GCS) score ≤ 12) traumatic brain injury. * Pregnancy or obstetrical surgery. * Patient refusal of blood products. * Inability to provide consent.
Contact & Investigator
Guillaume Martel, MD, MSc, FRCSC, FACS
PRINCIPAL INVESTIGATOR
Ottawa Hospital Research Institute
Frequently Asked Questions
Who can join the NCT06718439 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Blood Transfusion. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06718439 currently recruiting?
Yes, NCT06718439 is actively recruiting participants. Contact the research team at zvanterpool@ohri.ca for enrollment information.
Where is the NCT06718439 trial being conducted?
This trial is being conducted at Ottawa, Canada.
Who is sponsoring the NCT06718439 clinical trial?
NCT06718439 is sponsored by Ottawa Hospital Research Institute. The principal investigator is Guillaume Martel, MD, MSc, FRCSC, FACS at Ottawa Hospital Research Institute. The trial plans to enroll 384 participants.